Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus

Karanikas, V;Lurquin, C.;Colau, Didier;van Baren, Nicolas;Coulie, Pierre;et.al.
(2003) Journal of Immunology — Vol. 171, n° 9, p. 4898-4904 (2003)

Files

KARANIKAS_JIMMUNNOL2003.pdf
  • Restricted Access
  • Adobe PDF
  • 542.08 KB

Details

Authors
  • Karanikas, V
    Author
  • Lurquin, C.
    Author
  • Colau, DidierUCLouvain
    Author
  • Author
  • Author
  • Connerotte, ThierryUCLouvain
    Author
  • Corbiere, VéroniqueUCLouvain
    Author
  • Boon, ThierryUCLouvain
    Author
  • Author
Show more
Abstract
We have analyzed the T cell responses of HLA-A1 metastatic melanoma patients with detectable disease, following vaccination with a recombinant ALVAC virus, which bears short MAGE-1 and MAGE-3 sequences coding for antigenic peptides presented by HLA-A1. To evaluate the anti-MAGE CTL responses, we resorted to antigenic stimulation of blood lymphocytes under limiting dilution conditions, followed by tetramer analysis and cloning of the tetramer-positive cells. The clones were tested for their specific lytic ability and their TCR sequences were obtained. Four patients who showed tumor regression were analyzed, and an anti-MAGE-3.A1 CTL response was observed in three of these patients. Postvaccination frequencies of anti-MAGE-3.A1 CTL were 3 x 10(-6), 3 x 10(-3), and 3 x 10(-7) of the blood CD8 T cells, respectively. These three responses were monoclonal. No anti-MAGE-1.A1 CTL response was observed. These results indicate that, like peptide immunization, ALVAC immunization produces monoclonal responses. They also suggest that low-level antivaccine CTL responses can initiate a tumor regression process. Taken together, our analysis of anti-MAGE-3.A1 T cell responses following peptide or ALVAC vaccination shows a degree of correlation between CTL response and tumor regression, but firm conclusions will require larger numbers.
Affiliations

Citations

Karanikas, V., Lurquin, C., Colau, D., van Baren, N., De Smet, C., Lethé, B., Connerotte, T., Corbiere, V., Demoitie, M., Lienard, D., Dréno, B., Velu, T., Boon, T., & Coulie, P. (2003). Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. Journal of Immunology, 171(9), 4898-4904. https://doi.org/10.4049/jimmunol.171.9.4898 (Original work published 2003)